Person:
SÜMBÜL, BİLGE

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
BİLGE
Last Name
SÜMBÜL
Name
Email Address
Birth Date

Filters

2021 - 20222
Reset filters

Settings

Author: DOYMAZ, MEHMET ZIYA × Author: DOYMAZ, Mehmet Ziya × Has files: true × Type: Article ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Screening of mecC Gene in Methicillin Resistant Staphylococcus aureus Isolates
    (2022-04-01T00:00:00Z) Ceylan, Ayse Nur; SÜMBÜL, BİLGE; DOYMAZ, Mehmet Ziya; SÜMBÜL, BİLGE; DOYMAZ, MEHMET ZIYA
    Objective: The diagnosis and treatment of mecC positive methicillin resistant Staphylococcus aureus (MRSA) isolates pose a significant problem in clinical microbiology and infectious disease practices. The studies on the frequency of mecC positive isolates in Turkey is rather scarce. In the present study, we aimed to investigate the presence of mecA, mecC, spa and pvu genes in MRSA strains isolated from various clinical specimens submitted to Clinical Microbiology Laboratories of Bezmialem Vakıf Hospital. Methods: We performed nucleic acid extraction and multiplex polymerase chain reaction (PCR) to 126 MRSA strains to detect mecC, mecA, spa and pvl genes. Results: According to the multiplex PCR results of 126 MRSA strains studied, 126 (100%) had mecA, 107 (85%) had spa, and 3 (2%) had pvl genes. We performed another polymerase chain reaction protocol and spa genes were identified in 19 of specimens, which were found negative priorly. Conclusion: Considering the factors that a university medical center where the study was conducted provided a tertiary healthcare service to a large metropolitan area in Istanbul and none of the isolates carried mecC gene might indicate that mecC gene carrying MRSA isolates did not pose a significant public health threat in Turkey.
  • Thumbnail Image
    PublicationOpen Access
    Microbiological Diagnosis of COVID-19
    (2021-02-01T00:00:00Z) SÜMBÜL, BİLGE; DOYMAZ, Mehmet Ziya; SÜMBÜL, BİLGE; DOYMAZ, MEHMET ZIYA
    Various tests are used to detect the severe acute respiratory syndrome-coronirus-2 (SARS-CoV-2) virus causing Coronavirus disease-19 (COVID-19) disease. Today, the realtime (RT) -PCR test combined with the reverse-transcription reaction is the gold standard method used to diagnose SARS-CoV-2. This method is referred to as quantitative realtime PCR (RT-qPCR) because it determines not only the presence of SARS-CoV-2 but also the amount of virus in the specimen. Due to the use of virus-specific primers, the specificity of the tests is considered to be 100%. For this test, swab samples taken from the upper respiratory tract such as nasopharyngeal and throat, samples from the lower respiratory tract areas such as sputum and bronchoalveolar lavage fluid, rectal swab, feces, serum and urine samples are preferred. Correct use of personal protective equipment (PPE) by healthcare professionals during sampling and testing is important. Rapid antigen tests used in addition to RT-qPCR test for the diagnosis of SARS-CoV-2 are advantageous due to the theoretical rapid result time and low cost, but the sensitivity of this method is known to be very low. Virus detection in cell cultures can be used to detect SARS-CoV-2, but it is not for routine diagnostic because the results take a long time, require labor, and expertise. Serological tests are frequently used in the diagnosis and follow-up of this disease. These are mainly ELISA, CLIA, immunofluorescence test (IFA), western blot (WB), protein microarray (microarray) and neutralization. ELISA based immunoglobulin (Ig)M and IgG antibody tests have more than 95% specificity in the diagnosis of COVID-19.